meet our team
CLick on an image to learn more about each member of our team
*McInnes A, Ettensohn MF. 2019. Chap. 5: Ketamine Therapy for Treatment-Resistant Depression. In Winkelman MJ, Sessa B (Eds.), Advances in Psychedelic Medicine: State-of-the-Art Therapeutic Applications (pp. 81-101). Santa Barbara, CA: ABC-CLIO, LLC.
^Dugar A, Ettensohn MF, Levine SP. 2018. Ketamine and Its Pharmacologic Profile in Psychiatric Disorders. Psychiatr Ann. 48(4):170-174 https://doi.org/10.3928/00485713-20180314-01.
^Klise A, Lerner B, Ettensohn MF, Levine SP. 2018. Ketamine Treatment for Mood Disorders. Psychiatr Ann. 48(4):175-179 https://doi.org/10.3928/00485713-20180315-01.
^Ettensohn MF, Markey S, Levine SP. 2018. Considering Ketamine Treatment for Comorbid Pain, Depressive and Substance Use Disorders. Psychiatr Ann. 48(4):180-183 https://doi.org/10.3928/00485713-20180312-02.
^Dougherty JW III, Ettensohn MF, Levine SP. 2018. Beyond Depression: Ketamine and Glutamatergic Agents for PTSD, OCD, and Other Potential Applications. Psychiatr Ann. 48(4):184-188 https://doi.org/10.3928/00485713-20180312-03.
* Dr. Ettensohn has no financial interest in sales of the above texts.
Created and Managed by CPC